Product
C7R-GD2.CART cells
1 clinical trial
6 indications
Indication
NeuroblastomaIndication
OsteosarcomaIndication
Ewing SarcomaIndication
Relapsed RhabdomyosarcomaIndication
Uveal melanomaIndication
Phyllodes Breast TumorClinical trial
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)Status: Active (not recruiting), Estimated PCD: 2024-06-01